Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration
Open accessThe DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.
Abstract
Current therapy to slow disease progression in patients with neovascular age-related macular degeneration (AMD) entails regular intravitreal anti-vascular endothelial growth factor (VEGF) injections, often indefinitely. Little is known about the burden imposed on patients by this repetitive treatment schedule and how this can be best managed. The aim of this study was to explore the psychosocial impact of repeated intravitreal injections on patients with neovascular AMD. Forty patients (16 males, 24 females) with neovascular AMD undergoing anti-VEGF treatment were recruited using purposive sampling from a private ophthalmology practice and public hospital in Melbourne. Patients were surveyed using the Macular Disease Treatment Satisfaction Questionnaire (MacTSQ; Bradley, Health Psychology Research Unit, Surrey, England) and underwent semi-structured, one-on-one interviews. Interview topics were: treatment burden and satisfaction; tolerability; barriers to adherence; treatment motivation; and patient education. Interviews were audio recorded and thematic analysis performed using NVivo 10 (QSR International, Doncaster, Australia). Patients recognised the importance of treatment to preserve eyesight, yet experienced significant psychosocial and practical burden from the treatment schedule. Important issues included treatment-related anxiety, financial considerations and transport burden placed on relatives or carers. Many patients were restricted to sedentary activities post-injection owing to treatment side effects. Patients prioritised treatment, often sacrificing family, travel and social commitments owing to a fear of losing eyesight if treatment was not received. Whilst anti-VEGF injections represent the current mainstay of treatment for neovascular AMD, the ongoing treatment protocol imposes significant burden on patients. An understanding of the factors that contribute to the burden of treatment may help inform strategies to lessen its impact and assist patients to better manage the challenges of treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The repeated injections may take a significant toll on the patients’ emotional wellbeing and quality of life [11, 69], adversely affecting adherence and potentially leading to undertreatment and deterioration of the condition [70].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [69]
Citations
Cites
(2014) · Cited by 15,747
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Age-related macular degeneration
Jager, R. D., Mieler, W. F., & Miller, J. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801537 · Cited by 1,379
Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Wordsworth, S., & Reeves, B. C. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.04.015 · Cited by 781
Chakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Culliford, L. A., & Reeves, B. C. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61501-9 · Cited by 748 · cited 1×
“Psychometric evaluation was later conducted in the Inhibit VEGF in Age-related Choroidal Neovascularisation (IVAN) clinical trial (Chakravarthy et al., 2012, 2013).”
MethodHo, A. C., Busbee, B. G., Regillo, C. D., Wieland, M. R., Van Everen, S. A., Li, Z., Rubio, R. G., & Lai, P. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.009 · Cited by 590
(2020) · Clinical ophthalmology · doi:10.2147/opth · Cited by 589
Drug Design, Development and Therapy
(2020) · Drug Design Development and Therapy · doi:10.2147/dddt · Cited by 558
Age-related macular degeneration
Coleman, H. R., Chan, C.-C., Ferris, F. L., & Chew, E. Y. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61759-6 · Cited by 542
Busbee, B. G., Ho, A. C., Brown, D. M., Heier, J. S., Suñer, I. J., Li, Z., Rubio, R. G., & Lai, P. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.10.014 · Cited by 500 · cited 1×
“The safety and efficacy of anti-VEGF treatment has been vigorously demonstrated in several randomised clinical trials (Busbee et al., 2013; Chakravarthy et al., 2012; Rosenfeld et al., 2006; Semeraro et al., 2014).”
Background
Research works printed but not linked: 4
- Avci, R., Inan, S., Polat, O., Kusbeci, T., Yavas, G., & Dogan, M. (2013). Non-compliance to the intravitreal anti-VEGF injections in patients with exudative age-related macular degeneration. Paper presented at the ASRS 31st Annual Meeting, Toronto.
- 10.1111/ceo.2011.39.issue-2 · doi:10.1111/ceo.2011.39.issue-2
- Mitchell, J., Brose, L., & Bradley, C. (2007). Design of a measure of satisfaction with treatment for Macular Degeneration (MacTSQ). Paper presented at the International Society for Quality of Life Research Meeting, Canada.
- Regillo, C. (2014). Anti-VEGF maintenance therapy for neovascular AMD. Retina Today, 9, 63–67.
Cited by
Okada, M., Mitchell, P., Finger, R. P., Eldem, B., Talks, S. J., Hirst, C., Paladini, L., Barratt, J., Wong, T. Y., & Loewenstein, A. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2020.07.060 · Cited by 214
Wykoff, C. C., Clark, W. L., Nielsen, J. S., Brill, J. V., Greene, L. S., & Heggen, C. L. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.2-a.s3 · Cited by 124
Grishanin, R., Vuillemenot, B., Sharma, P., Keravala, A., Greengard, J., Gelfman, C., Blumenkrantz, M., Lawrence, M., Hu, W., Kiss, S., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2018.11.003 · Cited by 127
“Despite the efficacy of protein-based anti-VEGFA therapies, a key drawback to their use is the need for chronic intravitreal (IVT) injections every 4 to 8 weeks that involve frequent office visits, injection discomfort, and logistical burden placed on relatives and caretakers in addition to costs of treatment.(7) As a…”
BackgroundThe burden of neovascular age-related macular degeneration: a patient’s perspective
Spooner, K., Mhlanga, C., Hong, T., Broadhead, G., & Chang, A. (2018) · Clinical ophthalmology · doi:10.2147/opth.s185052 · Cited by 125
Monés, J., Singh, R. P., Bandello, F., Souied, E., Liu, X., & Gale, R. (2020) · Ophthalmologica · doi:10.1159/000502747 · Cited by 110
Metadata
- Authors
- Boyle, J., Vukicevic, M., Koklanis, K., Itsiopoulos, C., & Rees, G.
- Affiliations
- La Trobe University (AU)
- Royal Children's Hospital (AU)
- The University of Melbourne (AU)
- Corresponding author
- Boyle, Jessica
- Venue
- Psychology, Health & Medicine
- Publisher
- Informa UK Limited
- Published
- 2017-01-09
- Volume
- 23
- Issue
- 2
- Pages
- 127-140
- ISSN
- 1354-8506 (ISSN-L)
- 1465-3966
- OpenAlex
- W2568773933
- Cited by
- 119
- References
- 28
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 8 · 2023: 11 · 2022: 16 · 2021: 28 · 2020: 13 · 2019: 7 · 2018: 4 · 2017: 3
- FWCI
- 7.20
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- cc-by
- Locations
- Psychology Health & Medicine (publishedVersion)
- PubMed (publishedVersion)
- RMIT Research Repository (RMIT University Library) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Victorian Branch
- La Trobe University
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Keywords
- neovascular age-related macular degeneration, anti-VEGF therapy, intravitreal injection, treatment burden, patient satisfaction, medication adherence, treatment-related anxiety, financial burden, caregiver burden, treatment side effects, patient education, treatment motivation, psychosocial impact
- MeSH terms
- Aged, Aged, 80 and over, Australia, Female, Humans, Male, Middle Aged, Patient Acceptance of Health Care, Angiogenesis Inhibitors, Vascular Endothelial Growth Factors, Wet Macular Degeneration, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. https://app.cochat.ai/papers/10.1080/13548506.2016.1274040
- The paper
- Boyle, J., Vukicevic, M., Koklanis, K., Itsiopoulos, C., & Rees, G. (2018). Experiences of patients undergoing repeated intravitreal anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration. Psychology, Health & Medicine. https://doi.org/10.1080/13548506.2016.1274040
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.